1. Home
  2. QDEL vs PGEN Comparison

QDEL vs PGEN Comparison

Compare QDEL & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

N/A

Current Price

$16.22

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Logo Precigen Inc.

PGEN

Precigen Inc.

N/A

Current Price

$3.12

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QDEL
PGEN
Founded
1979
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
QDEL
PGEN
Price
$16.22
$3.12
Analyst Decision
Hold
Buy
Analyst Count
4
5
Target Price
$32.75
$7.67
AVG Volume (30 Days)
1.2M
3.6M
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
45.35
N/A
EPS
N/A
N/A
Revenue
$2,730,200,000.00
$230,981,000.00
Revenue This Year
$3.51
$342.78
Revenue Next Year
$3.86
$478.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.08
$1.11
52 Week High
$37.24
$5.47

Technical Indicators

Market Signals
Indicator
QDEL
PGEN
Relative Strength Index (RSI) 32.27 33.62
Support Level N/A $2.99
Resistance Level $30.65 $5.10
Average True Range (ATR) 1.18 0.17
MACD -0.06 -0.00
Stochastic Oscillator 16.64 8.47

Price Performance

Historical Comparison
QDEL
PGEN

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Share on Social Networks: